Author

A. Zampella

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:differential expression· 2 Research Focus:host-pathogen & immune response· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1

Frequent Co-Authors

E. Distrutti· 5 shared M. Biagioli· 5 shared S. Fiorucci· 5 shared S. Marchiano· 4 shared A. Carino· 3 shared A. Donini· 3 shared B. Catalanotti· 3 shared C. Di Giorgio· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

E. Distrutti

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Cancer BiologybioRxivSep 30, 2023

Bile Acids Serve As Endogenous Antagonists Of The Leukemia Inhibitory Factor (LIF) Receptor in Oncogenesis

C. Di Giorgio, E. Morretta, A. Lupia…·S. Fiorucci

The paper shows bile acids, specifically GDCA, inhibit LIFR in gastric cancer, suggesting potential for bile acid-based therapies in LIF-driven oncogenesis.

DOI 10.1016/j.bcp.2024.116134

humanorganoid / primary culture

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 5, 2022

Next generation sequencing analysis of gastric cancer identifies the leukemia inhibitory factor receptor (LIFR) as a driving factor in gastric cancer progression and as a predictor of poor prognosis

C. Di Giorgio, S. Marchiano, E. Marino…·S. Fiorucci

This study identifies LIFR as a key driver in gastric cancer progression and a predictor of poor prognosis through RNA-seq analysis of patient samples.

DOI 10.1101/2022.05.05.490785

humanbulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivFeb 24, 2021

Discovery of a AhR flavonoid agonist that counter-regulates ACE2 expression in rodent models of inflammation and attenuates ACE2-SARS-CoV2 interaction in vitro

M. Biagioli, S. Marchiano, R. Roselli…·S. Fiorucci

This study identifies pelargonidin, a flavonoid that reduces ACE2 expression and SARS-CoV2 binding in inflamed colons via AhR activation.

DOI 10.1016/j.bcp.2021.114564

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivFeb 2, 2021

Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

A. Carino, L. Graziosi, S. Marchiano…·S. Fiorucci

This study identifies histotype-specific molecular signatures in gastric cancer using transcriptomic analysis, finding AQP9, CARD14, and CXCR2 as prognostic markers.

DOI 10.3389/fonc.2021.663771

humanbulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivJun 10, 2020

Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region

A. Carino, F. Moraca, B. Fiorillo…·S. Fiorucci

This study identifies steroidal agents that inhibit SARS-CoV-2 entry by targeting binding pockets on the Spike protein's receptor-binding domain.

DOI 10.3389/fchem.2020.572885

experimental assayhost-pathogen & immune response

𝕏 PostBluesky